{
    "ticker": "OCUP",
    "name": "Ocuphire Pharma, Inc.",
    "description": "Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of eye diseases. Founded in 2018, Ocuphire focuses on addressing unmet medical needs in ocular health through its proprietary product candidates. The company\u2019s lead product, Nyxol, is being developed for the treatment of pharmacologically induced mydriasis (dilated pupils) and presbyopia (age-related blurry near vision). With a commitment to advancing eye care, Ocuphire aims to enhance patients' quality of life by improving visual function and reducing the burden of eye diseases. The company has made significant strides in clinical trials and is actively engaged in expanding its pipeline to include additional therapeutic candidates targeting various ocular conditions. Ocuphire is also exploring potential partnerships to expedite the development and commercialization of its products, leveraging collaborations to bring innovative therapies to market. Its mission is to become a leader in the field of ophthalmology, providing cutting-edge solutions that address both common and complex eye disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Farmington Hills, Michigan, USA",
    "founded": "2018",
    "website": "https://www.ocuphire.com",
    "ceo": "Megan R. O'Rourke",
    "social_media": {
        "twitter": "https://twitter.com/OcuphirePharma",
        "linkedin": "https://www.linkedin.com/company/ocuphire-pharma/"
    },
    "investor_relations": "https://investors.ocuphire.com",
    "key_executives": [
        {
            "name": "Megan R. O'Rourke",
            "position": "CEO"
        },
        {
            "name": "Michael K. W. Wong",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ocular Therapeutics",
            "products": [
                "Nyxol"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ocuphire Pharma, Inc. | Innovative Eye Care Solutions",
        "meta_description": "Discover Ocuphire Pharma, Inc., a leader in developing therapies for eye diseases. Explore our pipeline and commitment to improving ocular health.",
        "keywords": [
            "Ocuphire",
            "Ocular Health",
            "Biopharmaceuticals",
            "Nyxol",
            "Eye Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Ocuphire Pharma known for?",
            "answer": "Ocuphire Pharma is known for developing innovative therapies for the treatment of eye diseases, particularly its lead product Nyxol."
        },
        {
            "question": "Who is the CEO of Ocuphire Pharma?",
            "answer": "Megan R. O'Rourke is the CEO of Ocuphire Pharma, Inc."
        },
        {
            "question": "Where is Ocuphire Pharma headquartered?",
            "answer": "Ocuphire Pharma is headquartered in Farmington Hills, Michigan, USA."
        },
        {
            "question": "What are Ocuphire Pharma's main products?",
            "answer": "Ocuphire Pharma's main product is Nyxol, which is being developed for various ocular conditions."
        },
        {
            "question": "When was Ocuphire Pharma founded?",
            "answer": "Ocuphire Pharma was founded in 2018."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "SNY"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "BMY"
    ]
}